Study of Bevacizumab in Combination with Alternating XELIRI and XELOX in Metastatic Colorectal Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

Bevacizumab plus alternating XELOX/XELIRI

3 cycles of XELOX+bevacizumab alternating with 3 cycles XELIRI+bevacizumab until disease progression

Trial Locations (1)

Department of Oncology, Helsinki

All Listed Sponsors

lead

Pia Osterlund

OTHER